Slide #16 in ENTA's new slide deck (#msg-128915696) is apropos to our prior discussion of FXR agonists.
ENTA now splits this drug class into four sub-classes (a 2x2 matrix) based on whether they are steroids and on whether they have a carboxylic-acid linker.
ICPT's Ocaliva (OCA) and other bile acids are steroids with a carboxylic-acid linker.
ENTA's EDP-305 is a steroid with a non-carboxylic-acid linker.
GILD's GS-9674, NVS' LJN452, and various FXR agonists deeper in ENTA's pipeline are non-steroidal.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.